Advanced search
Publication Cover
Leukemia & Lymphoma Volume 48, 2007 - Issue 12
Submit an article Journal homepage
112
Views
18
CrossRef citations to date
0
Altmetric
Original Article: Clinical

Phase II study of denileukin diftitox for previously treated indolent non-Hodgkin lymphoma: Final results of E1497

Timothy M. Kuzel Feinberg School of Medicine-Northwestern University, Chicago, ILCorrespondence[email protected]
,
Shuli Li Biostatistical Science and Computational Biology, Dana-Farber Cancer Institute, Boston, MA
,
John Eklund Feinberg School of Medicine-Northwestern University, Chicago, IL
,
Francine Foss New England Medical Center, Boston, MA
,
Randy Gascoyne British Columbia Cancer Agency, Vancouver, Canada
,
Neil Abramson Baptist Regional Cancer Institute, Jacksonville, FL
,
John F. Schwerkoske United Hospital, St. Paul, MN
,
Edie Weller Biostatistical Science and Computational Biology, Dana-Farber Cancer Institute, Boston, MA
&
Sandra J. Horning Stanford University, Stanford, CA for the Eastern Cooperative Oncology Group
 show all
Pages 2397-2402 | Received 15 Aug 2007, Accepted 19 Sep 2007, Published online: 01 Jul 2009

References

  • Bacha P, Williams D P, Waters C, Williams J M, Murphy J R, Strom T B. Interleukin 2 receptor-targeted cytotoxicity. Interleukin 2 receptor-mediated action of a diphtheria toxin-related interleukin 2 fusion protein. J Exp Med 1988; 167: 612–622
  • Kiyokawa T, Williams D P, Snider C E, Waters C A, Nichols J C, Strom T B, et al. Protein engineering of DAB-IL-2 fusion toxins to increase biologic potency. Ann N Y Acad Sci 1991; 636: 331–339
  • Williams D P, Parker K, Bacha P, Bishai W, Borowski M, Genbauffe F, et al. Diphtheria toxin receptor binding domain substitution with interleukin-2: genetic construction and properties of a diphtheria toxin-related interleukin-2 fusion protein. Protein Eng 1987; 1: 493–498
  • LeMaistre C F, Saleh M N, Kuzel T M, Foss F, Platanias L C, Schwartz G, et al. Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2. Blood 1998; 91: 399–405
  • Paschal B R. Remission of follicular non-Hodgkin's lymphoma with denileukin diftitox (ONTAK) after progression during rituximab, CHOP and fludarabine therapy. Leuk Lymphoma 2003; 44: 731–733
  • Dang N H, Hagemeister F B, Pro B, McLaughlin P, Romaguera J E, Jones D, et al. Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma. J Clin Oncol 2004; 22: 4095–4102
  • Cox D R. Analysis of Binary Data. Metheun and Company, London 1970
  • Frankel A E, Fleming D R, Hall P D, Powell B L, Black J H, Leftwich C, et al. A phase II study of DT fusion protein denileukin diftitox in patients with fludarabine-refractory chronic lymphocytic leukemia. Clin Cancer Res 2003; 9(10 Part 1)3555–3561
  • Morgan S J, Seymour J F, Prince H M, Westerman D A, Wolf M M. Confirmation of the activity of the interleukin-2 fusion toxin denileukin diftitox against chemorefractory chronic lymphocytic leukemia, including cases with chromosome 17p deletions and without detectable CD25 expression. Clin Cancer Res 2004; 10: 3572–3575
  • Re G G, Waters C, Poisson L, Willingham M C, Sugamura K, Frankel A E. Interleukin 2 (IL-2) receptor expression and sensitivity to diphteria fusion toxin DAB389IL-2 in cultured hematopoietic cells. Cancer Res 1996; 56: 2590–2595
  • Dave S S, Wright G, Tan B, Rosenwald A, Gascoyne R D, Chan W C, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004; 351: 2159–2169
  • van der Vliet H J, Koon H B, Atkins M B, Balk S P, Exley M A. Exploiting regulatory T-cell populations for the immunotherapy of cancer. J Immunother (1997) 2007; 30: 591–595
  • Foss F M, Bacha P, Osann K E, Demierre M F, Bell T, Kuzel T. Biological correlates of acute hypersensitivity events with DAB(389)IL-2 (denileukin diftitox, ONTAK) in cutaneous T-cell lymphoma: decreased frequency and severity with steroid premedication. Clin Lymphoma 2001; 1: 298–302
  • Duzova A, Cetin M, Gumruk F, Yetgin S. Acute tumour lysis syndrome following a single-dose corticosteroid in children with acute lymphoblastic leukaemia. Eur J Haematol 2001; 66: 404–407
  • Malik I A, Abubakar S, Alam F, Khan A. Dexamethasone-induced tumor lysis syndrome in high-grade non-Hodgkin's lymphoma. South Med J 1994; 87: 409–411
  • Sparano J, Ramirez M, Wiernik P H. Increasing recognition of corticosteroid-induced tumor lysis syndrome in non-Hodgkin's lymphoma. Cancer 1990; 65: 1072–1073
  • Olsen E, Duvic M, Frankel A, Kim Y, Martin A, Vonderheid E, et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 2001; 19: 376–388

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.